RU2006119464A - Способ распыления-охлаждения с применением экструдера для получения композиций азитромицина в мультичастицах, предпочтительно содержащих полоксамер и глицерид - Google Patents
Способ распыления-охлаждения с применением экструдера для получения композиций азитромицина в мультичастицах, предпочтительно содержащих полоксамер и глицерид Download PDFInfo
- Publication number
- RU2006119464A RU2006119464A RU2006119464/15A RU2006119464A RU2006119464A RU 2006119464 A RU2006119464 A RU 2006119464A RU 2006119464/15 A RU2006119464/15 A RU 2006119464/15A RU 2006119464 A RU2006119464 A RU 2006119464A RU 2006119464 A RU2006119464 A RU 2006119464A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- molten mixture
- azithromycin
- multiparticulates
- carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Glanulating (AREA)
Claims (16)
1. Способ получения мультичастиц, включающий стадии
(a) получения в экструдере расплавленной смеси, содержащей азитромицин и фармацевтически приемлемый носитель;
(b) доставки указанной расплавленной смеси со стадии (a) к распыляющим устройствам для образования капель из указанной смеси; и
(c) охлаждения указанных капель со стадии (b) для получения указанных мультичастиц.
2. Способ получения мультичастиц, включающий стадии
(a) получения расплавленной смеси, содержащей азитромицин и фармацевтически приемлемый носитель;
(b) доставки указанной расплавленной смеси со стадии (a) к распыляющим устройствам для образования капель из указанной смеси; и
(c) охлаждения указанных капель со стадии (b) для получения указанных мультичастиц,
где концентрация сложных эфиров азитромицина в указанных мультичастицах составляет менее чем приблизительно 1 мас.%.
3. Способ по п.2, где указанную расплавленную смесь получают в экструдере.
4. Способ по п.1 или 2, где указанную расплавленную смесь получают при температуре обработки, которая по меньшей мере на 10°C выше температуры плавления указанного носителя.
5. Способ по п.1 или 2, где указанная расплавленная смесь содержит суспензию кристаллического дигидрата азитромицина в указанном носителе.
6. Способ по п.1 или 2, где температура указанной расплавленной смеси составляет по меньшей мере приблизительно 70°C и меньше, чем приблизительно 130°C.
7. Способ по п.1 или 2, где указанную расплавленную смесь расплавляют по меньшей мере в течение 5 с и приблизительно менее чем за 20 мин перед формированием указанных капель на стадии (b).
8. Способ по п.2, где концентрация сложных эфиров азитромицина в указанных мультичастицах составляет менее чем приблизительно 0,1 мас.%.
9. Способ по п.1 или 2, где указанные мультичастицы содержат от приблизительно 20 до приблизительно 75 мас.% указанного азитромицина и от приблизительно 25 до приблизительно 80% указанного носителя.
10. Способ по п.9, где указанный носитель выбирают из группы, состоящей из восков, глицеридов и их смесей.
11. Способ по п.10, дополнительно включающий агент, улучшающий растворение, где указанный агент, улучшающий растворение, составляет от приблизительно 0,1 до приблизительно 30 мас.% указанной мультичастицы.
12. Способ по п.1 или 2, где указанные мультичастицы содержат от приблизительно 35 до приблизительно 55 мас.% указанного азитромицина.
13. Способ по п.12, где указанные мультичастицы содержат от приблизительно 40 до приблизительно 65 мас.% указанного носителя и указанный носитель выбирают из группы, состоящей из восков, глицеридов и их смесей.
14. Способ по п.13, где указанный носитель выбирают из группы, состоящей из синтетического воска, микрокристаллического воска, парафинового воска, воска карнаубы, пчелиного воска, глицерилмоноолеата, глицерилмоностеарата, глицерилпальмитостеарата, полиэтоксилированных производных касторового масла, гидрогенизированных растительных масел, глицерила моно-, ди- или трибегенатов, глицерилтристеарата, глицерилтрипальмитата и их смесей.
15. Способ по п.14, где указанный носитель дополнительно содержит от приблизительно 0,1 до приблизительно 15 мас.% агента, улучшающего растворение.
16. Способ по п.15, где указанный агент, улучшающий растворение, выбирают из группы, состоящей из полоксамеров, простых алкиловых эфиров полиоксиэтилена, полиэтиленгликоля, полисорбатов, сложных алкиловых эфиров полиоксиэтилена, лаурилсульфата натрия, сложных моноэфиров сорбитана, стеарилового спирта, цетилового спирта, полиэтиленгликоля, глюкозы, сахарозы, ксилита, сорбита, мальтита, хлорида натрия, хлорида калия, хлорида лития, хлорида кальция, хлорида магния, сульфат натрия, сульфат калия, карбонат натрия, сульфат магния, фосфата калия, аланина, глицина и их смеси.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52724403P | 2003-12-04 | 2003-12-04 | |
US60/527,244 | 2003-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006119464A true RU2006119464A (ru) | 2007-12-20 |
Family
ID=34652484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006119464/15A RU2006119464A (ru) | 2003-12-04 | 2004-11-22 | Способ распыления-охлаждения с применением экструдера для получения композиций азитромицина в мультичастицах, предпочтительно содержащих полоксамер и глицерид |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050158391A1 (ru) |
EP (1) | EP1701702A1 (ru) |
JP (1) | JP2007513143A (ru) |
KR (2) | KR20060109481A (ru) |
CN (1) | CN1889931A (ru) |
AR (1) | AR046468A1 (ru) |
AU (1) | AU2004294813A1 (ru) |
BR (1) | BRPI0416535A (ru) |
CA (1) | CA2547773A1 (ru) |
IL (1) | IL175745A0 (ru) |
NO (1) | NO20062389L (ru) |
RU (1) | RU2006119464A (ru) |
TW (1) | TW200528138A (ru) |
WO (1) | WO2005053653A1 (ru) |
ZA (1) | ZA200604495B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011039686A1 (en) | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
EP4035683A1 (en) * | 2011-12-12 | 2022-08-03 | Adare Pharmaceuticals USA, Inc. | Sustained release particle formulations |
WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
EP3694491A1 (en) | 2017-10-10 | 2020-08-19 | Capsugel Belgium NV | Gelling multiparticulates |
CN109288798A (zh) * | 2018-12-08 | 2019-02-01 | 海南医学院 | 一种阿奇霉素掩味微球的制备方法 |
WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
WO2021094953A1 (en) | 2019-11-14 | 2021-05-20 | Pfizer Inc. | 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms |
US20230181463A1 (en) * | 2020-05-15 | 2023-06-15 | Massachusetts Institute Of Technology | Oleogel and oleopaste compositions and uses thereof |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3590A (en) * | 1844-05-17 | Rule or measure | ||
US6650A (en) * | 1849-08-14 | Edmund blunt | ||
US2955956A (en) * | 1957-05-15 | 1960-10-11 | Morton Salt Co | Process and apparatus for coating granules |
US4092089A (en) * | 1974-04-06 | 1978-05-30 | Bayer Aktiengesellschaft | Apparatus for the preparation of melt-sprayed spherical phenacetin granules |
US4086346A (en) * | 1974-04-06 | 1978-04-25 | Bayer Aktiengesellschaft | Preparation of melt-sprayed spherical phenacetin granules |
US4053264A (en) * | 1976-01-30 | 1977-10-11 | United Technologies Corporation | Apparatus for making metal powder |
US4293570A (en) * | 1979-04-02 | 1981-10-06 | Chimicasa Gmbh | Process for the preparation of sweetener containing product |
SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
KR920006865B1 (ko) * | 1984-05-18 | 1992-08-21 | 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 | 입자나 액적을 피복하는 방법과 장치 |
US4874611A (en) * | 1985-06-20 | 1989-10-17 | The Dow Chemical Company | Microencapsulated ant bait |
US5100592A (en) * | 1986-03-12 | 1992-03-31 | Washington University Technology Associated, Inc. | Method and apparatus for granulation and granulated product |
US5019302A (en) * | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
US5456932A (en) * | 1987-04-20 | 1995-10-10 | Fuisz Technologies Ltd. | Method of converting a feedstock to a shearform product and product thereof |
US5236734A (en) * | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US5387431A (en) * | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
WO1989000576A1 (en) * | 1987-07-09 | 1989-01-26 | Pfizer Inc. | Azithromycin dihydrate |
WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US5064650A (en) * | 1988-04-19 | 1991-11-12 | Southwest Research Institute | Controlled-release salt sensitive capsule for oral use and adhesive system |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
US5084287A (en) * | 1990-03-15 | 1992-01-28 | Warner-Lambert Company | Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat |
US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
DE69111287T2 (de) * | 1990-04-18 | 1995-12-21 | Asahi Chemical Ind | Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung. |
US5183690A (en) * | 1990-06-25 | 1993-02-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Starch encapsulation of biologically active agents by a continuous process |
GB9014646D0 (en) * | 1990-07-02 | 1990-08-22 | Courtaulds Coatings Holdings | Coating compositions |
US5194262A (en) * | 1990-10-22 | 1993-03-16 | Revlon Consumer Products Corporation | Encapsulated antiperspirant salts and deodorant/antiperspirants |
US5196199A (en) * | 1990-12-14 | 1993-03-23 | Fuisz Technologies Ltd. | Hydrophilic form of perfluoro compounds and method of manufacture |
US5292657A (en) * | 1990-12-31 | 1994-03-08 | Pioneer Hi-Bred International, Inc. | Process for preparing rotary disc fatty acid microspheres of microorganisms |
US5143662A (en) * | 1991-02-12 | 1992-09-01 | United States Surgical Corporation | Process for preparing particles of bioabsorbable polymer |
US5405617A (en) * | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
GB9201857D0 (en) * | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
DE4214272A1 (de) * | 1992-05-04 | 1993-11-11 | Nukem Gmbh | Verfahren und Vorrichtung zur Herstellung von Mikrokugeln |
CA2095776C (en) * | 1992-05-12 | 2007-07-10 | Richard C. Fuisz | Rapidly dispersable compositions containing polydextrose |
ATE136459T1 (de) * | 1992-05-22 | 1996-04-15 | Goedecke Ag | Verfahren zur herstellung retardierter arzneimittelzubereitungen |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
TW271400B (ru) * | 1992-07-30 | 1996-03-01 | Pfizer | |
US5348758A (en) * | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
US5569467A (en) * | 1993-05-15 | 1996-10-29 | Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) | Process for the preparation of microballs and microballs thus obtained |
IL109770A0 (en) * | 1993-05-29 | 1994-11-28 | Smithkline Beecham Corp | Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby |
US5935600A (en) * | 1993-09-10 | 1999-08-10 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing comestible unit and product therefrom |
US5597416A (en) * | 1993-10-07 | 1997-01-28 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
AT401871B (de) * | 1994-01-28 | 1996-12-27 | Gebro Broschek Gmbh | Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung |
ES2270426T3 (es) * | 1994-03-18 | 2007-04-01 | Supernus Pharmaceuticals, Inc. | Sistema de suministros de farmacos emulsionados. |
US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
DE69524214T3 (de) * | 1994-05-06 | 2008-05-15 | Pfizer Inc. | Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe |
DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5582855A (en) * | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5556652A (en) * | 1994-08-05 | 1996-09-17 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
US5601761A (en) * | 1994-09-26 | 1997-02-11 | The Dow Chemical Company | Encapsulated active materials and method for preparing same |
US5965164A (en) * | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
US5683720A (en) * | 1994-10-28 | 1997-11-04 | Fuisz Technologies Ltd. | Liquiflash particles and method of making same |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
FR2732621B1 (fr) * | 1995-04-10 | 1997-06-06 | Rhone Poulenc Chimie | Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention |
KR100404293B1 (ko) * | 1995-05-02 | 2004-02-18 | 다이쇼 세이야꾸 가부시끼가이샤 | 경구투여용조성물 |
US5883103A (en) * | 1995-06-07 | 1999-03-16 | Shire Laboratories Inc. | Oral acyclovir delivery |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
AU6403196A (en) * | 1995-06-30 | 1997-02-05 | Baylor University | Polyester/carboxylic acid composite materials |
EP0784933A3 (en) * | 1995-10-16 | 1997-11-26 | Leaf, Inc. | Extended release of additives in comestible products |
US5919489A (en) * | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
DE19629753A1 (de) * | 1996-07-23 | 1998-01-29 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
TW474824B (en) * | 1996-09-13 | 2002-02-01 | Basf Ag | The production of solid pharmaceutical forms |
US5948407A (en) * | 1997-03-19 | 1999-09-07 | Shire Laboratories Inc. | Oral induction of tolerance to parenterally administered non-autologous polypeptides |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
DE19729487A1 (de) * | 1997-07-10 | 1999-01-14 | Dresden Arzneimittel | Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix |
SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
EP1028712B1 (en) * | 1997-09-19 | 2005-01-12 | Shire Laboratories Inc. | Solid solution beadlet |
IE970731A1 (en) * | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
EP1525882B1 (en) * | 1997-12-08 | 2012-08-08 | Nycomed GmbH | Administration form comprising an acid-labile active compound |
US6270804B1 (en) * | 1998-04-03 | 2001-08-07 | Biovail Technologies Ltd. | Sachet formulations |
US6086920A (en) * | 1998-08-12 | 2000-07-11 | Fuisz Technologies Ltd. | Disintegratable microspheres |
US6117452A (en) * | 1998-08-12 | 2000-09-12 | Fuisz Technologies Ltd. | Fatty ester combinations |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AU2928701A (en) * | 2000-01-04 | 2001-07-16 | Teva Pharmaceutical Industries Ltd. | Preparation method of azithromycin dihydrate |
IT1320176B1 (it) * | 2000-12-22 | 2003-11-26 | Nicox Sa | Dispersioni solide di principi attivi nitrati. |
DE60211130T2 (de) * | 2001-02-13 | 2006-11-30 | Astrazeneca Ab | Neue formulierung mit modifizierter freisetzung |
AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
BR0307344A (pt) * | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
-
2004
- 2004-11-22 CN CNA2004800358177A patent/CN1889931A/zh active Pending
- 2004-11-22 EP EP04798952A patent/EP1701702A1/en not_active Withdrawn
- 2004-11-22 AU AU2004294813A patent/AU2004294813A1/en not_active Abandoned
- 2004-11-22 WO PCT/IB2004/003839 patent/WO2005053653A1/en active Application Filing
- 2004-11-22 KR KR1020067011027A patent/KR20060109481A/ko not_active Ceased
- 2004-11-22 JP JP2006542040A patent/JP2007513143A/ja not_active Abandoned
- 2004-11-22 RU RU2006119464/15A patent/RU2006119464A/ru unknown
- 2004-11-22 CA CA002547773A patent/CA2547773A1/en not_active Abandoned
- 2004-11-22 BR BRPI0416535-7A patent/BRPI0416535A/pt not_active IP Right Cessation
- 2004-11-22 KR KR1020087015425A patent/KR20080064209A/ko not_active Withdrawn
- 2004-12-01 TW TW093137051A patent/TW200528138A/zh unknown
- 2004-12-03 US US11/003,856 patent/US20050158391A1/en not_active Abandoned
- 2004-12-03 AR ARP040104514A patent/AR046468A1/es unknown
-
2006
- 2006-05-18 IL IL175745A patent/IL175745A0/en unknown
- 2006-05-24 NO NO20062389A patent/NO20062389L/no not_active Application Discontinuation
- 2006-06-01 ZA ZA200604495A patent/ZA200604495B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0416535A (pt) | 2007-01-09 |
TW200528138A (en) | 2005-09-01 |
KR20060109481A (ko) | 2006-10-20 |
AU2004294813A1 (en) | 2005-06-16 |
CN1889931A (zh) | 2007-01-03 |
IL175745A0 (en) | 2006-09-05 |
US20050158391A1 (en) | 2005-07-21 |
JP2007513143A (ja) | 2007-05-24 |
NO20062389L (no) | 2006-06-16 |
EP1701702A1 (en) | 2006-09-20 |
AR046468A1 (es) | 2005-12-07 |
CA2547773A1 (en) | 2005-06-16 |
KR20080064209A (ko) | 2008-07-08 |
ZA200604495B (en) | 2008-03-26 |
WO2005053653A1 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006119464A (ru) | Способ распыления-охлаждения с применением экструдера для получения композиций азитромицина в мультичастицах, предпочтительно содержащих полоксамер и глицерид | |
EP0084865B1 (en) | Propylene glycol diester solutions of pge-type compounds | |
CA2436287A1 (en) | Fast dissolving tablet | |
RU2002100645A (ru) | Противогрибковая композиция для перорального введения, содержащая интраконазол, и способ получения такой композиции | |
US9539295B2 (en) | Cannabidiol (CBD) enriched alcohol | |
ATE407666T1 (de) | Kaubare weichkapseln mit verbesserten verabreichungseigenschaften sowie verfahren zu deren herstellung | |
RU2006115596A (ru) | Твердые дозированные формы, включающие фибрат и статин | |
RU2001118035A (ru) | Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы | |
JP2005525993A5 (ru) | ||
EP0858325A1 (fr) | Formulation pharmaceutique lyophilisee stable | |
JPH0149127B2 (ru) | ||
JP2005518423A5 (ru) | ||
JP2010150283A (ja) | エスシタロプラムを含む結晶性組成物 | |
JP2008539230A (ja) | 脂質相を含む薬学的投与形態 | |
DE602006014607D1 (de) | Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung | |
EA200200951A1 (ru) | Фармацевтические композиции | |
CO4900080A1 (es) | Microesferas farmaceuticas de acido valproico para administracion oral | |
FR2620331A1 (fr) | Suppositoires a base de calcitonine | |
CA2535340A1 (en) | Fast dissolving tablet | |
RU2005114390A (ru) | Получение твердых дозированных форм с использованием сшитого не термопластичного носителя | |
JP2013139469A (ja) | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 | |
HRP20010650A2 (en) | Controlled-release compositions of betahistine | |
US20030072809A1 (en) | Pharmaceutical granules | |
ES2277622T3 (es) | Derivados de 1-alilergotalcaloides, procedimiento para su preparacion y su utilizacion para la profilaxis y terapia de la migraña. | |
RU2006119505A (ru) | Стабилизированная композиция азитромицина |